JO3773B1 - معدلات p2x7 - Google Patents
معدلات p2x7Info
- Publication number
- JO3773B1 JO3773B1 JOP/2014/0094A JOP20140094A JO3773B1 JO 3773 B1 JO3773 B1 JO 3773B1 JO P20140094 A JOP20140094 A JO P20140094A JO 3773 B1 JO3773 B1 JO 3773B1
- Authority
- JO
- Jordan
- Prior art keywords
- iib
- iia
- formulas
- compounds
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
يتعلق هذا الاختراع بمركبات الصيغة (I، Ia، IIa و IIb): يتعلق الاختراع أيضاً بتركيبات صيدلية تشتمل على مركبات الصيغة (I، Ia، IIa و IIb). وتكون طرق عمل واستخدام مركبات الصيغة (I، Ia، IIa و IIb) أيضاً داخل مجال الاختراع.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786260P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3773B1 true JO3773B1 (ar) | 2021-01-31 |
Family
ID=50543353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0094A JO3773B1 (ar) | 2013-03-14 | 2014-03-12 | معدلات p2x7 |
Country Status (33)
Country | Link |
---|---|
US (7) | US10112937B2 (ar) |
EP (3) | EP2970267B3 (ar) |
JP (1) | JP6293861B2 (ar) |
KR (4) | KR102319857B1 (ar) |
CN (2) | CN110003200B (ar) |
AR (2) | AR095530A1 (ar) |
AU (4) | AU2014239291B2 (ar) |
BR (1) | BR112015023142B1 (ar) |
CA (1) | CA2906085C (ar) |
CL (3) | CL2015002655A1 (ar) |
CY (1) | CY1119110T1 (ar) |
DK (2) | DK2970267T6 (ar) |
EA (1) | EA028816B1 (ar) |
ES (2) | ES2635318T7 (ar) |
HK (1) | HK1218541A1 (ar) |
HR (1) | HRP20171168T4 (ar) |
HU (1) | HUE032877T2 (ar) |
IL (1) | IL240880B (ar) |
JO (1) | JO3773B1 (ar) |
LT (1) | LT2970267T (ar) |
ME (1) | ME02802B (ar) |
MX (2) | MX364796B (ar) |
PH (1) | PH12015501930A1 (ar) |
PL (1) | PL2970267T6 (ar) |
PT (2) | PT2970267T (ar) |
RS (1) | RS56315B2 (ar) |
SG (2) | SG11201507259UA (ar) |
SI (1) | SI2970267T1 (ar) |
TW (2) | TWI599567B (ar) |
UA (1) | UA116467C2 (ar) |
UY (3) | UY39888A (ar) |
WO (1) | WO2014152604A1 (ar) |
ZA (1) | ZA201507627B (ar) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
JP6467404B2 (ja) | 2013-03-14 | 2019-02-13 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7モジュレーター |
TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | P2x7調節劑 |
AU2014230814B2 (en) | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015172196A1 (en) * | 2014-05-13 | 2015-11-19 | Monash University | Heterocyclic compounds and use of same |
HUE047208T2 (hu) | 2014-09-12 | 2020-04-28 | Boehringer Ingelheim Int | A katepszin-C spirociklikus inhibitorai |
EP3191492B1 (en) | 2014-09-12 | 2019-01-09 | Janssen Pharmaceutica NV | P2x7 modulators |
KR20190123812A (ko) | 2015-04-24 | 2019-11-01 | 시오노기 앤드 컴파니, 리미티드 | 6원 헤테로환 유도체 및 그를 함유하는 의약 조성물 |
ES2757052T3 (es) * | 2015-07-31 | 2020-04-28 | Merck Patent Gmbh | Derivados heterocíclicos bicíclicos |
AU2017345923B2 (en) | 2016-10-17 | 2021-11-11 | Shionogi & Co., Ltd. | Bicyclic nitrogenated heterocyclic derivative and pharmaceutical composition containing same |
EP3548613B1 (en) | 2016-12-02 | 2021-01-27 | Fraunhofer Gesellschaft zur Förderung der Angewand | Bacterial glutaminyl cyclase inhibitors and use thereof in the treatment of periodontitis |
PT3609868T (pt) | 2017-03-13 | 2023-12-18 | Raqualia Pharma Inc | Derivados de tetra-hidroquinolina como antagonistas do recetor p2x7 |
WO2019099509A1 (en) * | 2017-11-14 | 2019-05-23 | Second Genome, Inc. | Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder |
EP3746429B1 (en) * | 2018-01-30 | 2022-03-09 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
KR20210069080A (ko) | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
CN109400605A (zh) * | 2018-11-27 | 2019-03-01 | 复旦大学附属中山医院 | 一种p2x7受体显像剂及其制备方法 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
WO2021064569A1 (en) * | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
JP7165647B2 (ja) | 2019-12-26 | 2022-11-04 | 信越化学工業株式会社 | 熱伝導性シリコーン樹脂組成物 |
CN114945561A (zh) * | 2020-01-13 | 2022-08-26 | 阿普塔生物治疗公司 | 新吡唑衍生物 |
KR20220157999A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
CN115894452A (zh) * | 2021-08-18 | 2023-04-04 | 四川大学 | 一种p2x7受体抑制剂 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
CA2093125C (en) | 1990-10-02 | 2003-12-16 | Warner-Lambert Company | Angiotensin ii antagonists |
WO2004014374A1 (en) * | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
BR0312913A (pt) | 2002-07-25 | 2005-07-12 | Pharmacia Italia Spa | Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
FR2857363B1 (fr) | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
AU2005277283A1 (en) | 2004-08-23 | 2006-03-02 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
JP2008528580A (ja) | 2005-01-27 | 2008-07-31 | アストラゼネカ・アクチエボラーグ | P2x7受容体の阻害剤である新規二環式芳香族化合物 |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
AU2008269177A1 (en) | 2007-06-21 | 2008-12-31 | Schering Corporation | Polycyclic Guanine Derivatives and use thereof |
CA2691512A1 (en) * | 2007-08-10 | 2009-02-19 | H. Lundbeck A/S | Heteroaryl amide analogues |
FR2921342B1 (fr) | 2007-09-20 | 2010-03-12 | Airbus France | Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
ES2376092T3 (es) | 2008-04-22 | 2012-03-08 | Janssen Pharmaceutica, N.V. | Antagonistas de p2x7 sustituidos con quinolina o isoquinolina. |
JP5063815B2 (ja) | 2008-11-25 | 2012-10-31 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体 |
WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
WO2010125102A1 (en) | 2009-04-29 | 2010-11-04 | Glaxo Group Limited | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
GB0907515D0 (en) * | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
US8871760B2 (en) | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
US9062044B2 (en) | 2009-10-23 | 2015-06-23 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
BR112012025101B1 (pt) | 2010-04-02 | 2021-08-31 | Ogeda S.A. | Compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e medicamento compreendendo os mesmos |
CN102844507A (zh) | 2010-04-16 | 2012-12-26 | 罗德里戈·格拉夫费尔南德斯 | 用于建筑物的可折叠结构 |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
US9273947B2 (en) | 2012-02-07 | 2016-03-01 | Lg Innotek Co., Ltd. | Sensing magnet apparatus for motor |
JP5205547B1 (ja) | 2012-04-20 | 2013-06-05 | 株式会社ノイズ研究所 | 放射信号可視化装置 |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
RU2662436C2 (ru) | 2012-10-15 | 2018-07-26 | Эпизайм, Инк. | Содержащие заместители бензольные соединения |
ES2632269T3 (es) | 2012-10-16 | 2017-09-12 | Janssen Pharmaceutica Nv | Moduladores de quinolinailo enlazados a metileno de ROR-gamma-t |
WO2014071031A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
PT2935248T (pt) | 2012-12-21 | 2018-04-05 | Plexxikon Inc | Compostos e métodos para a modulação de quinase e indicações associadas |
AU2013363957B2 (en) | 2012-12-21 | 2018-03-22 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
TW201446745A (zh) | 2013-02-08 | 2014-12-16 | Celgene Avilomics Res Inc | Erk抑制劑及其用途 |
NO335177B1 (no) | 2013-03-06 | 2014-10-13 | Cambi Technology As | Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse |
KR102230383B1 (ko) | 2013-03-06 | 2021-03-23 | 얀센 파마슈티카 엔.브이. | 히스타민 h4 수용체의 벤조이미다졸-2-일 피리미딘 조절제 |
JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
TWI599567B (zh) * | 2013-03-14 | 2017-09-21 | 健生藥品公司 | P2x7調節劑 |
HUE043568T2 (hu) | 2013-03-14 | 2019-08-28 | Glaxosmithkline Ip No 2 Ltd | 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk |
MX361375B (es) | 2013-03-14 | 2018-12-05 | Newlink Genetics Corp | Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano. |
MX2015012028A (es) | 2013-03-14 | 2016-02-11 | Curadev Pharma Private Ltd | Inhibidores de la ruta de quinurenina. |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
AU2014230814B2 (en) | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
JP6467404B2 (ja) | 2013-03-14 | 2019-02-13 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7モジュレーター |
US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
EP2989103B1 (en) | 2013-03-29 | 2019-02-20 | Ogeda Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
EP3191492B1 (en) | 2014-09-12 | 2019-01-09 | Janssen Pharmaceutica NV | P2x7 modulators |
EP3191488B1 (en) | 2014-09-12 | 2019-08-14 | Janssen Pharmaceutica NV | P2x7 modulating n-acyl-triazolopyrazines |
KR20210069080A (ko) | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
WO2021064569A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
-
2014
- 2014-03-12 TW TW103108579A patent/TWI599567B/zh active
- 2014-03-12 JO JOP/2014/0094A patent/JO3773B1/ar active
- 2014-03-12 TW TW106128537A patent/TWI644671B/zh active
- 2014-03-14 AR ARP140101138A patent/AR095530A1/es active IP Right Grant
- 2014-03-14 PT PT147188577T patent/PT2970267T/pt unknown
- 2014-03-14 ME MEP-2017-160A patent/ME02802B/me unknown
- 2014-03-14 KR KR1020157029102A patent/KR102319857B1/ko active IP Right Grant
- 2014-03-14 EP EP14718857.7A patent/EP2970267B3/en active Active
- 2014-03-14 KR KR1020227010005A patent/KR102516711B1/ko active IP Right Grant
- 2014-03-14 BR BR112015023142-0A patent/BR112015023142B1/pt active IP Right Grant
- 2014-03-14 EP EP18204727.4A patent/EP3495365A1/en not_active Withdrawn
- 2014-03-14 SG SG11201507259UA patent/SG11201507259UA/en unknown
- 2014-03-14 UY UY0001039888A patent/UY39888A/es active IP Right Grant
- 2014-03-14 WO PCT/US2014/027522 patent/WO2014152604A1/en active Application Filing
- 2014-03-14 AU AU2014239291A patent/AU2014239291B2/en active Active
- 2014-03-14 ES ES14718857T patent/ES2635318T7/es active Active
- 2014-03-14 HU HUE14718857A patent/HUE032877T2/hu unknown
- 2014-03-14 EP EP17172541.9A patent/EP3239151B1/en active Active
- 2014-03-14 CA CA2906085A patent/CA2906085C/en active Active
- 2014-03-14 US US14/775,432 patent/US10112937B2/en active Active
- 2014-03-14 MX MX2015012095A patent/MX364796B/es active IP Right Grant
- 2014-03-14 UY UY0001039887A patent/UY39887A/es not_active Application Discontinuation
- 2014-03-14 UY UY0001035469A patent/UY35469A/es active IP Right Grant
- 2014-03-14 PT PT17172541T patent/PT3239151T/pt unknown
- 2014-03-14 DK DK14718857.7T patent/DK2970267T6/en active
- 2014-03-14 US US14/212,669 patent/US9066946B2/en active Active
- 2014-03-14 SI SI201430279T patent/SI2970267T1/sl unknown
- 2014-03-14 LT LTEP14718857.7T patent/LT2970267T/lt unknown
- 2014-03-14 PL PL14718857T patent/PL2970267T6/pl unknown
- 2014-03-14 CN CN201811523767.7A patent/CN110003200B/zh active Active
- 2014-03-14 JP JP2016502469A patent/JP6293861B2/ja active Active
- 2014-03-14 CN CN201480027363.2A patent/CN105209464B/zh active Active
- 2014-03-14 DK DK17172541.9T patent/DK3239151T3/en active
- 2014-03-14 EA EA201591748A patent/EA028816B1/ru unknown
- 2014-03-14 ES ES17172541T patent/ES2704024T3/es active Active
- 2014-03-14 UA UAA201510002A patent/UA116467C2/uk unknown
- 2014-03-14 KR KR1020217034732A patent/KR102500076B1/ko active IP Right Grant
- 2014-03-14 SG SG10201700889PA patent/SG10201700889PA/en unknown
- 2014-03-14 KR KR1020237010674A patent/KR20230049754A/ko not_active Application Discontinuation
- 2014-03-14 RS RS20170758A patent/RS56315B2/sr unknown
-
2015
- 2015-05-18 US US14/714,714 patent/US9464084B2/en active Active
- 2015-08-27 IL IL240880A patent/IL240880B/en active IP Right Grant
- 2015-09-02 PH PH12015501930A patent/PH12015501930A1/en unknown
- 2015-09-09 MX MX2022011795A patent/MX2022011795A/es unknown
- 2015-09-14 CL CL2015002655A patent/CL2015002655A1/es unknown
- 2015-10-13 ZA ZA2015/07627A patent/ZA201507627B/en unknown
-
2016
- 2016-06-07 HK HK16106529.9A patent/HK1218541A1/zh unknown
- 2016-09-07 US US15/258,320 patent/US10150765B2/en active Active
-
2017
- 2017-07-17 AU AU2017206153A patent/AU2017206153B2/en active Active
- 2017-07-25 CY CY20171100794T patent/CY1119110T1/el unknown
- 2017-07-31 HR HRP20171168TT patent/HRP20171168T4/hr unknown
- 2017-10-16 CL CL2017002609A patent/CL2017002609A1/es unknown
- 2017-10-16 CL CL2017002610A patent/CL2017002610A1/es unknown
-
2018
- 2018-11-20 US US16/196,140 patent/US10703749B2/en active Active
-
2019
- 2019-05-07 AU AU2019203186A patent/AU2019203186B2/en active Active
-
2020
- 2020-06-25 US US16/911,428 patent/US11225478B2/en active Active
-
2021
- 2021-07-23 AR ARP210102071A patent/AR123048A2/es unknown
- 2021-09-21 AU AU2021236451A patent/AU2021236451B2/en active Active
-
2022
- 2022-01-14 US US17/576,644 patent/US11820770B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3773B1 (ar) | معدلات p2x7 | |
PH12019500176A1 (en) | Heterocyclic compounds and ther uses | |
PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
PH12015501720A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
IN2015DN03029A (ar) | ||
SV2014004770A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen | |
MX2017003254A (es) | 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina. | |
MX2015008766A (es) | Compuestos cbd fluorados, composiciones y usos de los mismos. | |
MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
MX364069B (es) | Moduladores de la proteína activadora de 5-lipoxigenasa. | |
PH12015501933A1 (en) | Novel pyridine derivatives | |
MX345926B (es) | Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas. | |
AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
MY180006A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2015016603A (es) | Composiciones de corticosteroides. | |
MX2015009377A (es) | Compuestos radiomarcados. | |
MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
LV15016A (lv) | N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas | |
IN2013CH02437A (ar) | ||
IN2013MU02279A (ar) | ||
UA91886U (uk) | 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол |